INTRODUCTION
Adenovirus infections are associated with a variety of clinical syndromes, and are usually self-limited. However, severe illness has been reported, especially in military recruits and compromised hosts, but has also been associated with new genomic variants [Kajon et al., 1990; Louie et al., 2008] . In order to investigate the current epidemiology of adenovirus infections in the United States, the University of Iowa Center for Emerging Infectious Diseases (CEID) and 22 US laboratories collaborated in a national surveillance program for emerging adenovirus infections from July 2004 to April 2007. Laboratories routinely sent adenovirus-positive clinical specimens to the University of Iowa where the specimens were sequence typed using a hexon gene typing strategy [Lu and Erdman, 2006] . The collaboration resulted in the characterization of more than 3,000 clinical adenovirus isolates. In November 2006, the Clinical Virology Laboratory at Yale New Haven Hospital (YNHH) in New Haven, Connecticut, experienced a marked increase in the number of clinical specimens that were adenovirus positive. This report summarizes an investigation into this increase.
METHODS

Patient Samples
Samples were submitted to clinical laboratories for diagnostic testing and were not solicited for the purposes of the study. Specimens positive for adenovirus by direct fluorescent antibody staining (DFA), PCR, other rapid test, or culture were sent to the University of Iowa from 22 participating laboratories, including 14 civilian and 8 military sites, for typing and further analysis. Prior to participation, the study was approved by each institution's Institutional Review Board.
Clinical Information
For each specimen, the collection date, collection site, specimen source, patient birth date, gender, if hospitalized when specimen was collected, and if the subject had received a cellular or solid organ transplant during the previous 6 months was submitted. Information on race and ethnicity, clinical presentation, duration of hospitalization or intensive care, disposition, type of cancer, and chronic disease were obtained only from patients who were either <7 years of age or who had received a transplant within 6 months of their adenovirus detection: supplemental clinical information was obtained for all Ad3-infected patients at YNHH.
Laboratory Analysis
At the University of Iowa's CEID, viral DNA was extracted from submitted specimens or cultures, and analyzed according to published procedures to determine adenovirus type and genotype [Arens and Dilworth, 1988; Guo et al., 1988; Li and Wadell, 1988; Adrian et al., 1989; Golovina et al., 1991; Lu and Erdman, 2006] .
Statistical Analyses
The w 2 test and Fisher's exact test were used to examine potential risk factor associations. The proportional odds model was used to examine risk factors for severe adenovirus infection. Analyses were performed using SAS, version 9.1 (SAS Institute). In a recent study, we reported the identification of two new Ad3 variants Ad3a50 and Ad3a51 (LeBeck et al., submitted) . The CT outbreak is largely explained by a marked increase in the clinical detections of the novel Ad3a51 strain (Table I and Fig. 1 ). To the authors' knowledge, Ad3a51 has never been detected in the United States before the CT outbreak.
RESULTS
From
In general, the outbreak patients were healthy children <7 years of age, who suffered from acute respiratory infection but were not hospitalized. In the variables examined before or during the outbreak, including conjunctivitis (P ¼ 0.0565), there were no statistically significant differences identified (Table I) . Supplemental clinical information obtained on all YNHH Ad3-infected patients showed directionally higher incidence of wheezing, rash, and asthma among patients infected with the newly described variant types, Ad3a50 and Ad3a51 compared to Ad3a2 and other Ad3. However, these differences were not statistically significant (data not shown).
Multivariable risk factor modeling (Table II) for adenovirus 3 disease severity (death or intensive care unit stay vs. hospitalization vs. other disease) revealed that age was an important factor (controling for chronic diseases). Specifically, children under 2 years of age (OR 5.9; 95% CI 1.9-19.0) and from 2 to 3 years of age (OR 3.7; 95% CI 1.1-12.2) were at increased risk of severe Ad3 clinical disease when compared to subjects above. When modeling for severe adenovirus infection or for pneumonia, no statistically significant risk factor associations were found.
While most infections were mild, ten of the outbreak patients developed pneumonia and one of the outbreak patients died (patient infected with Ad3a51). The one death reflects the only Ad3-associated death reported from among the 576 Ad3 isolates collected from among the 14 civilian sites during our surveillance. The patient was a child of 3 years and 11 months of age with a congenital oral-facial condition. She was doing well until she developed adenovirus pneumonia in January 2007. She was admitted to the hospital and died 1 month after admission.
DISCUSSION
Adenovirus type 3 is most commonly recognized as a cause of pharyngoconjunctival fever, sometimes with gastrointestinal symptoms. Outbreaks associated with childrens' camps, swimming pools or lakes, chronic care facilities, and hospitals have been reported [Brummitt et al., 1988; Li and Wadell, 1988; Kajon et al., 1990;  Zarraga et al., 1992; Singh-Naz et al., 1993; Chang et al., 2008] . Although rare, severe morbidity and deaths due to Ad3 can occur [Brummitt et al., 1988; Zarraga et al., 1992; Singh-Naz et al., 1993; Barker et al., 2003] . Epidemic outbreaks of Ad3 involving several genome types of the same serotype have been documented [Li and Wadell, 1988] . Most recently a community outbreak of Ad3 was reported in Taiwanese children [Chang et al., 2008] . Only 15 of 172 isolates from the outbreak were typed by RFLP and all belonged to genotype Ad3a2. In the present study, 161 Ad3 positive specimens were genotyped by REA. Our findings are consistent with findings of previous Ad3 outbreak investigations in its demonstration of Ad3 genomic variability [Foy et al., 1968; Brummitt et al., 1988; Zarraga et al., 1992; SinghNaz et al., 1993; Price et al., 2001; Barker et al., 2003] . In particular, the discovery of two newly described variant types, Ad3a50 and Ad3a51 may explain not only the dramatic rise in incidence of Ad3 infections over such a brief period of time, but also the potential for these new variants to cause marked morbidity among susceptible populations.
This study has a number of limitations. Due to the specialized and tedious nature of whole genome REA, it is rarely performed. Thus, there is no central repository of reference material with which to compare our findings. However, we comprehensively studied the literature and are convinced of the uniqueness of the reported novel viral strains. While it is possible that our claim of the newness of the Ad3a51 strain is inaccurate, in another work we examined Ad3 specimens collected in California back to 1963 and found no evidence of this strain [Foy et al., 1968; Price et al., 2001; Barker et al., 2003] . The application of this technology has the potential to advance our understanding of outbreaks and severe infections.
In summary, an outbreak of adenovirus disease occurred in New Haven, CT from November 2006 to April 2007. Molecular typing revealed a twofold increase in Ad3 infections. REA identified three variant types, including two newly described variants, Ad3a50, and Ad3a51. The CT outbreak was largely explained by a marked increase in the novel Ad3a51 strain. This outbreak represents the first detection of Ad3a51 in the United States. Although most infections were mild, children less than 3 were at greater risk of severe disease.
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